ARG1 and chronic myelogenous leukemia, BCR-ABL1 positive: Several clinical studies have shown that imatinib reduces G-MDSC numbers, which exert immunosuppressive activity linked to arginase-1-induced inhibitory effect on T cells, in patients diagnosed with CML [37, 38].